

# Long-term efficacy and safety of V0034 CR 01B cream in patients with moderate-to-severe uraemic xerosis

<b>Submission date</b> 01/03/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 04/05/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 10/09/2008	<b>Condition category</b> Skin and Connective Tissue Diseases	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Mr Patrick Dupuy

### Contact details

Orfagen  
Parc Technologique du canal  
4 rue Marie Curie  
BP 22132  
Ramonville St Agne  
France  
31521

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

### Secondary identifying numbers

V00034 CR 308 (ORF)

# Study information

## Scientific Title

### Study objectives

Primary objective:

To demonstrate the long-term efficacy (response to treatment during initial therapy, time to relapse without treatment, durability and lesional recurrence during maintenance therapy) of V0034 CR 01B cream on uraemic xerosis in the real-life setting.

Secondary objectives:

1. To assess the local tolerance of V0034 CR 01B after long-term use
2. To assess the patient benefit and acceptability of V0034 CR 01B

Please note that as of the 18th January 2008 this record was updated. Changes are written under the relevant sections under the date 18/01/2008. Please also note that the anticipated end date of this trial has been extended to 30/09/2008. The previous anticipated end date of this trial was 30/09/2007. Please also note that the following countries of recruitment have been added to this record as of 18/01/2008: Hungary, Czech Republic, Latvia.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Approval from:

1. Comités de Protection des Personnes, Sud Méditerranée IV, Hôpital St Eloi (France), approved on 25th August 2006
2. Sächsische Landesärztekammer Ethics Committee (Germany), approved on 14th November 2006
3. Commission of bioethics at Wroclaw Medical University (Poland), approved on 30th September 2006
4. Center of Katerini, General Hospital of Katerini (Greece), approved on 20th October 2006
5. Center of Szeged, University of Szeged (Hungary), approval pending
6. Center of Praha, Charles University School of Medicine (Czech Republic), approval pending
7. Center of Riga, Latvian Dermatology Institute Ltd Clinic (Latvia), approval pending

### Study design

Periods I + II: randomised, double blind, parallel group study; period III: open-labelled, non-controlled, one-arm study

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Not specified

**Study type(s)**

Treatment

**Participant information sheet****Health condition(s) or problem(s) studied**

Uraemic xerosis

**Interventions**

The study will comprise three periods:

Period I: randomised, vehicle-controlled, double-blind, two-parallel group, comparative study (initial treatment period) - once daily application of V0034 CR 01B or its vehicle

Period II: randomised, double blind, two-parallel group study (treatment-free follow-up) - no topical treatment

Period III : open-labelled, non-controlled, one arm study (maintenance treatment period) - V0034 CR 01B application at dosage ad libitum

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

V0034 CR 01B cream

**Primary outcome measure**

1. Treatment response of xerosis on five test areas (right lower leg, left lower leg, forearm having no arterio-venous shunt, chest, dorsum of the neck), using a defined physicians five-point severity scale (Gammal severity scale). Treatment response will be defined as a score of zero or one on all test areas at the end of Period I, and a reduction of at least two grades on at least one test area (primary efficacy parameter, Period I).
2. Time to relapse, as defined as the time up to which patients have at least one test area with a severity score of at least two during the treatment-free follow-up (Period II). Only patients with no persisting lesions on day 28 will be evaluated for this parameter.

**Secondary outcome measures**

1. Change from baseline of the Gammal severity score of the five test areas, as assessed by the physicians. Total severity score (sum of scores of the test areas) and separate scores by test area will be presented. Recurrence rate (i.e. proportion of patients with at least one test area with a score of at least two) will be accounted during Period III.
2. Scaling measurement (mean optical density of squames [MOD], total surface area of squames [SURFT]) on one lower leg made by the physician, using D-Squame
3. Assessment of the global severity of xerosis and pruritus made by the patients, using 10-cm Visual Analogue Scales (VAS)
4. Life quality assessment performed by 12-item Short Form health survey (SF-12) (generic scale) and Dermatology Life Quality Index (DLQI) scales, made by the patients
5. Global agreement of the test product by the patients on efficacy and ease of use, using a four-point scale (very satisfactory to not satisfactory at all)

**Overall study start date**

18/12/2006

**Completion date**

30/09/2008

## **Eligibility**

**Key inclusion criteria**

1. Patients of both sexes, of at least 18 years of age
2. Women of childbearing potential having a reliable contraceptive method
3. Patients undergoing maintenance renal dialysis (MRD), i.e. either haemodialysis or peritoneal dialysis, due to chronic renal failure
4. Patients whose xerosis is related to their renal insufficiency status (uraemic xerosis)
5. Patients suffering from xerosis with a severity score of at least two, on at least one of the five tests areas (right lower leg, left lower leg, forearm with no arterio-venous shunt, chest, dorsum of the neck)

**Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

240 patients

**Key exclusion criteria**

1. Patients under 18 years of age
2. Women with childbearing potential having a positive pregnancy test at baseline
3. Patients undergoing renal dialysis for another reason than chronic renal insufficiency
4. Patients whose xerosis is due to another reason than their MRD status
5. Patients suffering from mild xerosis (i.e. score less than two on all the xerotic test areas)
6. Patients with a known history of allergy to one of the ingredients contained in the test product
7. Patients with an intercurrent condition which may interfere with a good conduct or the study parameters of the study
8. Patients treated with any other emollient/moisturising topical preparation within the seven days prior to study entry
9. Patients who participated in a study within the three months prior to study entry
10. Patients who are not affiliated to health insurance
11. Patients who are not able or willing to follow the study instructions

**Date of first enrolment**

18/12/2006

**Date of final enrolment**

30/09/2008

**Locations****Countries of recruitment**

Czech Republic

France

Germany

Greece

Hungary

Latvia

Poland

**Study participating centre****Orfagen**

Ramonville St Agne

France

31521

**Sponsor information****Organisation**

Orfagen (France)

**Sponsor details**

Parc Technologique du canal

4 rue Marie Curie

BP 22132

Ramonville St Agne

France

31521

**Sponsor type**

Industry

**Website**

[http://www.orfagen.com/homepage/0,7134,20877876\\_0\\_0\\_fr\\_FR\\_0,00.html?vid=20878546](http://www.orfagen.com/homepage/0,7134,20877876_0_0_fr_FR_0,00.html?vid=20878546)

# Funder(s)

## Funder type

Industry

## Funder Name

Orfagen (France)

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration